[Breast cancer: pathology, the cornerstone of therapeutic decision].
Tailoring adjuvant therapy in breast cancer patients relies on prognostic and predictive factors, most of which are currently established by histopathological analysis of tumors. The quality of the assessment of the former (i.e.: tumor size, lymph node status, tumor grade, HER2 status, and lymphovascular invasion) and the latter (estrogen and progesteron receptors expression, HER2 overexpression or amplification) is an essential prerequisite for an optimal therapeutic decision. If the prognostic and predictive values of multigenes signatures are confirmed by on-going clinical studies, this approach could enter the clinical practice in the coming years and result in improved accuracy of adjuvant therapies in breast cancer patients. This approach might especially allow avoiding overtreatment in patients at low risk of recurrence.
Fiche
Maryse
M
Institut universitaire de pathologie, CHUV, 1011 Lausanne. Maryse.fiche@chuv.ch
Lehr
Hans-Anton
HA
Perey
Lucien
L
Delaloye
Jean-Francois
JF
Jeanneret-Sozzi
Wendy
W
Bauer
Jean
J
Zaman
Khalil
K
D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged